

8890 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

MEDFV-W

18 January 1972

SUBJECT: Minutes of the Therapeutic Agents Board Meeting
and Adverse Drug Reaction Report

(5) Quinine Sulf 260mg; Aminophylline 195mg (Quinamm) --

(Disapproved because of high cost. Physicians favorably impressed and good patient acceptance for diabetics with leg cramps, but felt present lower cost item, Quinine Sulfate, was satisfactory.)

(6) Perphenazine Tablets, 8mg (Trilafon) --

(Presently stock 2 and 4mg, but 8mg would provide a much smaller volume of medication; however, since 8mg is non-standard, cost is prohibitive. It was decided to request DPSC to make the Trilafon 8mg a standard item so cost would be lower. If made standard, this request will be considered later.)

g. The following item was deleted by the Board - Sodium Sulfacetamide Ophthalmic Sol, 15% (Sulamyd). This will be replaced by Sod Sulfacetamide 10%, Phenylephrine Ophth Sol (Vasosulf).

h. Discussion of Darvon Compound-65 (Deleted by depot as a standard item) - This is one of the biggest volume items in Pharmacy. Plain Darvon, 65mg, does not have the same acceptance with either physician or patient - preference is approximately 10 - 1 in favor of D.C.-65. It was unanimously agreed by Board members to continue stockage of this item as a non-standard item. Through Department Chiefs, a physician/patient education program will be initiated with the aim of reducing requests for this item.

5. The Adverse Drug Reaction Committee, which meets as a sub-committee of the Therapeutic Agents Board, presented completed Drug Experience Report on Keflin Injection from Dept of Medicine to be submitted to the FDA. No additional adverse drug reactions have been submitted since the last meeting.

6. The Board adjourned at 1445 hours.

for William E. Thomas LTJ, MSC
CHARLES E. THOMAS
MAJ, MSC
Recorder

FRANK J. SHANNON, JR.
COL, MC
Chairman